RE: Announced At today’s briefing17 May 2020 18:48
When it comes to treating this quick-spreading virus, speed is also vital. The UK biotech Tiziana Life Sciences have accelerated development of their TZLS-501 treatment, in the hope that it can help patients suffering from respiratory failure.
“Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.” – Tiziana Life Sciences
Of this company is know to many of the big Bios, would they now be looking to take us lock stock and barrel? Surly worth a takeover if even a small segment what has been published here comes to fruition. What would the offer price be ? fag box calculations welcome. Thanks and GLA